Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06072794
Other study ID # VL-POI-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 6, 2023
Est. completion date December 2025

Study information

Verified date October 2023
Source Vitti Labs, LLC
Contact Mukesh Kumar, PhD
Phone 2407504893
Email mkumar@fdamap.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.


Description:

Premature ovarian insufficiency (POI) is a devastating disease for young women who have not yet completed childbearing. The prevalence of this condition is on the rise due to the increasing number of cancer survivors and the delay in childbearing age. Current treatment options available are very limited. Stem cell therapy has been shown to be beneficial and effective in various disease processes and the safety has been assessed in multiple clinical trials. The regenerative potential of mesenchymal stem cells is increasingly attributed to the paracrine effects of exosomes. Exosomes consist of bioactive lipids, nucleic acids, and proteins which play a key role in intercellular communication. Exosome therapy is considered a safe and effective therapy since it offers a cell-free approach. VL-PX10 is a decellularized exosome product derived from human placental derived mesenchymal stem cells. This interventional pilot study will investigate the ability of intravenous injection of VL-PX10 to restore steroidogenesis, folliculogenesis, and support quality of life improvement, resumption of menstruation, and reversal of infertility in patients with POI and diminished ovarian reserve. This is an open label study. All patients entering this study will be treated with VL-PX10. Participant duration will be approximately 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 9
Est. completion date December 2025
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 43 Years
Eligibility Inclusion Criteria: - Able to understand and communicate in English language - Female of age 18-43 years - Diagnosis of premature ovarian insufficiency based on ESHRE Guidelines (i) oligo/amenorrhea for at least 4 months, and (ii) an elevated FSH level >25 IU/L on two occasions >4 weeks apart, or diagnosis of low ovarian reserve defined as: Basal FSH value >10 IU/L or failure of prior attempts of assisted reproductive techniques due to limited ovarian response (poor responders) - Normal karyotype 46, XX, and no known history FMR1 premutation (fragile X syndrome) - Baseline AMH levels = 1.0 ng/mL - Presence of at least one ovary - Normal uterine anatomy (by any clinically and/or imaging acceptable methods) - Normal thyroid function as evident by normal serum Thyroid Stimulating Hormone (TSH) levels - For subjects who had contraception before, the duration of amenorrhea should be more than 3 months after discontinuation of the oral contraception pill (OCP) or more than 6 months after discontinuation of Depo Provera (or similar) therapies - Agree to report any pregnancy to the research staff immediately - Willing and able to comply with study requirements and follow up instructions - Patient with known history of endometriosis or polycystic ovarian syndrome - If subject is planning to pursue pregnancy: presence of at least unilateral tubal patency (with any clinically acceptable methods) Exclusion Criteria: - Currently pregnant or breast-feeding - Has a history of, or evidence of current gynecologic malignancy, breast cancer or other estrogen responsive cancer or any other malignancy within the past five years - Subjects with FMR1 premutation (fragile X syndrome), a BMP15 mutation or family history of a first degree relative with POI - Presence of adnexal masses indicating the need for further evaluation - Major mental health disorder that precludes participation in the study - Active substance abuse or dependence - Current or recent (within the past 2 weeks) use of the following medications: Oral or systemic corticosteroids, Hormones (estrogen, progestin, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with possible hormonal effects. Washout will be allowed (2 weeks from screening) - Subjects under hormonal treatments including hormone replacement therapy (HRT) for osteoporosis, cardiovascular disease, or recalcitrant vasomotor symptomatology within 3 months from screening - Subjects with a history of breast cancer or other estrogen responsive cancer within 5 years from screening - Subjects with existing malignant neoplasm, under active management for malignant neoplasm or under active surveillance for malignant neoplasm within 5 years from screening - Subjects with history of thromboembolic events such as pulmonary embolism, stroke, or ischemic heart disease - Subjects with uncontrolled hypertension, kidney disease, liver disease, or polycystic ovary syndrome (PCOS) as defined below: - Uncontrolled hypertension: Systolic BP = 140 and/or Diastolic BP =90 in patients taking anti-hypertensive treatment - Kidney Disease: an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m^2 (Incase the result is above/below acceptable range, one repeat test is acceptable) - Liver Disease: Serum aminotransferase (ALT or AST) levels > 2x ULN - PCOS criteria: Oligo-anovulation (Irregular periods), antral follicle count (AFC) >12 measuring 2-9mm, hyperandrogenism (elevated testosterone and DHEA levels), clinical hirsutism - Subjects with untreated endocrinopathies including Cushing's disease, thyroid disease, congenital adrenal hyperplasia and hyperprolactinemia - Subjects with intra-uterine devices (IUDs) - Subjects who are allergic to low-molecular-weight heparin sodium or human albumin - Medical conditions that are contraindicated in pregnancy - Type I or Type II diabetes mellitus, or if receiving antidiabetic medications within 3 months from screening - Known anemia (Hemoglobin < 11 g/dL) - History of deep venous thrombosis, and/or pulmonary embolus - History of cerebrovascular disease - History of contrast media allergy - Known heart disease (New York Heart Association Class II or higher) - Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) >2 times normal, or total bilirubin >2.5mg/dL) - Known Renal disease (defined as Blood urea nitrogen (BUN) >30 mg/dL or serum creatinine > 1.6 mg/dL)

Study Design


Intervention

Drug:
VL-PX10
VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.

Locations

Country Name City State
United States Optimal Health Associates Oklahoma City Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Vitti Labs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events The number of treatment-emergent adverse events. 2 years
Secondary Follicle Stimulating Hormone Levels 50% reduction in follicle stimulating hormone values. 2 years
Secondary Anti-Müllerian Hormone Levels 30% increase in anti-Müllerian hormone levels. 2 years
Secondary Estradiol Levels 30% increase in estradiol levels. 2 years
Secondary Antral Follicle Counts Increased antral follicle counts. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04972877 - Effect of Electro-acupuncture on Women With Diminished Ovarian Reserve N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Recruiting NCT05277948 - Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR) N/A
Recruiting NCT04711772 - Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
Recruiting NCT03670407 - Follicular Activation by Fragmentation of Ovarian Tissue N/A
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Not yet recruiting NCT02099916 - Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF Phase 2/Phase 3
Not yet recruiting NCT06081257 - The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve N/A
Recruiting NCT06426355 - The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR N/A
Recruiting NCT04275700 - Study of PRP in Women With Evidence of Diminished Ovarian Reserve N/A
Recruiting NCT06223178 - Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve N/A
Not yet recruiting NCT05577455 - Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients Phase 3
Not yet recruiting NCT05459493 - A Clinical Study of Chinese Herbal Compound TJAOA101 in Therapy of Diminished Ovarian Reserve Early Phase 1
Recruiting NCT05665010 - Precise Stratification of Genetic Risk of Ovarian Function Impairment
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Recruiting NCT06395623 - Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics
Recruiting NCT05847283 - DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT N/A
Recruiting NCT05485610 - Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency) N/A
Completed NCT04237909 - Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency N/A